- Category: Experimental HIV Drugs
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir (Isentress), with fewer study withdrawal due to virological failure and less drug resistance, according to data from the SAILING trial presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Pedro Cahn from Fundacion Huesped in Buenos Aires discussed the findings at a press conference prior to his late-breaker presentation during the final session of the conference.
[Pedro Cahn speaks at IAS 2013 press conference, Kuala Lumpur, July 3, 2013]
P Cahn, AL Pozniak, H Mingrone, et al. Dolutegravir (DTG) is superior to raltegravir (RAL) in ART-experienced, integrase naive subjects: week 48 results from SAILING (ING111762). 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013). Kuala Lumpur, June 30-July 3, 2013. Abstract WELBB03.